-+ 0.00%
-+ 0.00%
-+ 0.00%

ZEO ScientifiX Partners With Pluri to Expand US Regenerative Medicine Business

PUBT·10/26/2026 11:09:32
Listen to the news
ZEO ScientifiX Partners With Pluri to Expand US Regenerative Medicine Business
  • ZEO ScientifiX entered a definitive partnership with Pluri to expand U.S. regenerative medicine manufacturing and commercialization.
  • Pluri will receive common stock representing 50% ownership at closing in exchange for defined manufacturing technology and know-how rights.
  • The agreement provides exclusive U.S. rights to Pluri's Cellav aesthetic product line, including future offerings.
  • Pluri will retain ownership of its underlying technology and intellectual property.
  • Closing is expected in the fourth quarter of 2026, subject to approvals and other conditions; neither company's stockholders need to approve.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ZEO Scientifix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260700PRIMZONEFULLFEED9852874) on October 26, 2026, and is solely responsible for the information contained therein.